OncoMatch/Clinical Trials/NCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Is NCT07284758 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cemsidomide and Dexamethasone for multiple myeloma.
Treatment: Cemsidomide · Dexamethasone — This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory drug (IKZF1/3 degrader)
must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader)
Must have received: proteasome inhibitor
must have included...a proteasome inhibitor
Must have received: anti-CD38 antibody
must have included...an anti-CD38 antibody
Must have received: T-cell engager
must have included...a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy
Must have received: CAR-T cell therapy
must have included...a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy
Cannot have received: (cemsidomide)
Previously treated with cemsidomide
Lab requirements
Blood counts
Kidney function
Liver function
Subjects need to have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Berenson Cancer Center · West Hollywood, California
- START Midwest · Grand Rapids, Michigan
- START San Antonio · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07284758 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages